The significant reduction in net loss and R&D expenses suggests improved financial efficiency following the completion of major clinical trials. However, investors should monitor whether the company can maintain this improved financial performance while continuing to invest in both its healthcare and solar business units. The $4.0 million raised provides runway, but future capital needs should be assessed as the company advances its OcuRing-K program and DeepSolar commercialization.
Price Chart
Executive Summary
PRF Technologies provided a year-end 2025 business update highlighting strategic progress across its healthcare and AI-driven solar platforms. The company reported a significant reduction in net loss from $14.6 million in 2024 to $4.8 million in 2025, primarily due to lower R&D expenses after completing extensive clinical trials in 2024, partially offset by new expenses from its acquisition of LayerBio. The company ended 2025 with $4.1 million in cash and positive working capital, having raised $4.0 million through at-the-market issuances.
Key Facts
- Net loss decreased from $14.6 million in 2024 to $4.8 million in 2025
- Research and development expenses decreased from $11.7 million in 2024 to $1.1 million in 2025
- General and administrative expenses remained stable at $3.0 million in both years
- Company ended 2025 with $4.1 million in cash and positive working capital of $1.9 million
- Raised $4.0 million through at-the-market issuances in 2025
- Completed strategic acquisition of DeepSolar and majority investment in LayerBio in 2025
Financial Impact
Net loss reduced by $9.8 million year-over-year, R&D expenses decreased by $10.6 million
Risk Factors
- The reduction in R&D expenses may not be sustainable as the company advances OcuRing-K to later-stage development
- The company has a history of significant losses and may need to raise additional capital
- Success depends on the commercialization of both OcuRing-K and DeepSolar solutions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-001786 |
| Document: zk2634960.htm | 0001178913-26-001786 |
| Document: 0001178913-26-001786-index-headers.html | 0001178913-26-001786 |
| Document: 0001178913-26-001786-index.html | 0001178913-26-001786 |
| Document: 0001178913-26-001786.txt | 0001178913-26-001786 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $0.7400 | awaiting T+60 | — | $0.7321 (−1.07%) |
Oct 23, 2026 4d ago | Press Release | $0.7400 | awaiting T+60 | — | $0.7321 (−1.07%) |
Sep 28, 2026 29d ago | 6-K | $0.9720 | awaiting T+60 | — | $0.7321 (−24.68%) |
Sep 24, 2026 4w ago | SC 13D | $0.9767 | awaiting T+60 | — | $0.7321 (−25.04%) |
Sep 16, 2026 5w ago | 6-K | $1.01 | awaiting T+60 | — | $0.7321 (−27.51%) |
Sep 4, 2026 7w ago | EFFECT | $0.9680 | awaiting T+60 | — | $0.7321 (+24.37%) |
Sep 3, 2026 7w ago | 6-K | $0.9792 | awaiting T+60 | — | $0.7321 (−25.23%) |
Sep 3, 2026 7w ago | Press Release | $0.9792 | awaiting T+60 | — | $0.7321 (−25.23%) |
Jul 27, 2026 13w ago | 6-K | $1.09 $0.7120 | ▼ −34.68% | ▼ −38.38% | $0.7321 (−32.83%) |
Jul 21, 2026 14w ago | 6-K | $1.20 $0.8180 | ▼ −31.83% | ▼ −35.81% | $0.7321 (−38.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers